BioCentury | Mar 28, 2017
Financial News

Antiva raises $22M series C round

...told BioCentury that Antiva expects results by YE18 from Phase Ib studies of lead compound ABI-1968...
...program or seek additional venture capital. Brace President and CEO Vinzenz Ploerer joined Antiva's board. Becky Simon HTI-1968 Antiva...
BioCentury | Aug 7, 2015
Financial News

Antiva raises $16M in series B

...existing investors also participated. The proceeds will be used to advance lead compound ABI-1968 ( HTI-1968...
BioCentury | Sep 22, 2014
Clinical News

Hera Therapeutics preclinical data

...In cultured human cell models, HTI-1968 blocked the replication of HPV types 11, 16, and 18...
...Seattle. HTI-1968 is a topical direct-acting antiviral. Hera Therapeutics Inc. , Del Mar, Calif. Product: HTI-1968...
Items per page:
1 - 3 of 3